Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
To determine the activity and response rate of AG-013736 in patients with advanced and
refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).